Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$2.05M$2.05M+130.9% vs Q2 2019 Net Income-$11.60M-$11.60MN/M vs Q2 2019 EPS Diluted-$0.28-$0.28N/M vs Q2 2019 Operating Income-$11,381,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$10,838,000N/M Margins · derivedOperating margin-556.3%+4364.7 pt vs Q2 2019
Net margin-566.8%+5062.5 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 7, 2020 · 38 d after period end